| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cornea | 8 | 2021 | 69 | 2.500 |
Why?
|
| Corneal Diseases | 7 | 2021 | 32 | 2.360 |
Why?
|
| Keratitis, Herpetic | 6 | 2018 | 9 | 2.350 |
Why?
|
| Visual Acuity | 12 | 2022 | 194 | 2.290 |
Why?
|
| Dry Eye Syndromes | 2 | 2022 | 5 | 1.720 |
Why?
|
| Acanthamoeba Keratitis | 2 | 2021 | 8 | 1.520 |
Why?
|
| Anti-Bacterial Agents | 6 | 2024 | 746 | 1.410 |
Why?
|
| Keratitis | 2 | 2019 | 22 | 1.300 |
Why?
|
| Simplexvirus | 4 | 2017 | 151 | 1.290 |
Why?
|
| Corneal Dystrophies, Hereditary | 2 | 2019 | 5 | 1.210 |
Why?
|
| Ophthalmologic Surgical Procedures | 5 | 2022 | 25 | 1.190 |
Why?
|
| Conjunctiva | 2 | 2018 | 19 | 1.180 |
Why?
|
| Corneal Stroma | 4 | 2021 | 12 | 1.130 |
Why?
|
| Keratoplasty, Penetrating | 5 | 2019 | 14 | 0.990 |
Why?
|
| Epithelium, Corneal | 3 | 2013 | 12 | 0.990 |
Why?
|
| Acanthamoeba | 2 | 2021 | 17 | 0.970 |
Why?
|
| Endophthalmitis | 1 | 2024 | 21 | 0.950 |
Why?
|
| Phosphorylcholine | 2 | 2021 | 28 | 0.920 |
Why?
|
| Eye Infections, Parasitic | 2 | 2019 | 4 | 0.870 |
Why?
|
| Lubricant Eye Drops | 1 | 2022 | 1 | 0.850 |
Why?
|
| Cataract Extraction | 3 | 2021 | 31 | 0.850 |
Why?
|
| Contact Lenses, Hydrophilic | 2 | 2019 | 2 | 0.850 |
Why?
|
| Eye Infections, Bacterial | 2 | 2019 | 14 | 0.840 |
Why?
|
| Ophthalmic Solutions | 2 | 2018 | 16 | 0.840 |
Why?
|
| Graves Ophthalmopathy | 1 | 2020 | 4 | 0.780 |
Why?
|
| Scleritis | 1 | 2020 | 5 | 0.780 |
Why?
|
| Corneal Edema | 3 | 2021 | 6 | 0.770 |
Why?
|
| Retinal Detachment | 1 | 2020 | 66 | 0.730 |
Why?
|
| Micrococcaceae | 1 | 2019 | 3 | 0.720 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2019 | 47 | 0.690 |
Why?
|
| Acyclovir | 2 | 2017 | 107 | 0.690 |
Why?
|
| Keratoconus | 2 | 2021 | 9 | 0.680 |
Why?
|
| Linezolid | 1 | 2018 | 3 | 0.670 |
Why?
|
| Keratoconjunctivitis | 1 | 2018 | 5 | 0.670 |
Why?
|
| Eye Infections, Fungal | 2 | 2016 | 14 | 0.670 |
Why?
|
| Mucormycosis | 2 | 2016 | 14 | 0.660 |
Why?
|
| Pseudolymphoma | 1 | 2018 | 9 | 0.660 |
Why?
|
| Conjunctivitis, Allergic | 1 | 2018 | 10 | 0.660 |
Why?
|
| Biofilms | 1 | 2018 | 42 | 0.650 |
Why?
|
| Vancomycin | 1 | 2018 | 72 | 0.640 |
Why?
|
| Prosthesis-Related Infections | 1 | 2018 | 58 | 0.640 |
Why?
|
| Humans | 49 | 2024 | 86643 | 0.630 |
Why?
|
| Prostheses and Implants | 1 | 2018 | 121 | 0.630 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 71 | 0.630 |
Why?
|
| Herpes Zoster Ophthalmicus | 1 | 2017 | 6 | 0.620 |
Why?
|
| Cicatrix | 1 | 2017 | 63 | 0.600 |
Why?
|
| Acrylamides | 1 | 2016 | 30 | 0.590 |
Why?
|
| Anthozoa | 1 | 2016 | 14 | 0.580 |
Why?
|
| Ocular Hypotension | 1 | 2015 | 3 | 0.550 |
Why?
|
| Orbit Evisceration | 1 | 2015 | 1 | 0.530 |
Why?
|
| Corneal Transplantation | 3 | 2021 | 9 | 0.530 |
Why?
|
| Orbital Cellulitis | 1 | 2015 | 4 | 0.530 |
Why?
|
| Retinal Vasculitis | 1 | 2015 | 1 | 0.530 |
Why?
|
| Eye Hemorrhage | 1 | 2015 | 2 | 0.520 |
Why?
|
| Astigmatism | 3 | 2021 | 10 | 0.520 |
Why?
|
| Trypan Blue | 1 | 2014 | 3 | 0.520 |
Why?
|
| Aspergillosis | 1 | 2015 | 41 | 0.510 |
Why?
|
| Coloring Agents | 1 | 2014 | 64 | 0.510 |
Why?
|
| Cataract | 3 | 2023 | 86 | 0.470 |
Why?
|
| Virus Internalization | 2 | 2010 | 39 | 0.470 |
Why?
|
| Intraoperative Complications | 1 | 2014 | 185 | 0.450 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 241 | 0.440 |
Why?
|
| Steroids | 3 | 2024 | 177 | 0.420 |
Why?
|
| Postoperative Complications | 3 | 2023 | 2207 | 0.420 |
Why?
|
| Eye | 2 | 2018 | 111 | 0.400 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2024 | 243 | 0.390 |
Why?
|
| Preservatives, Pharmaceutical | 2 | 2022 | 10 | 0.380 |
Why?
|
| Optic Nerve Diseases | 2 | 2021 | 18 | 0.370 |
Why?
|
| Endothelium, Corneal | 2 | 2020 | 19 | 0.360 |
Why?
|
| Strabismus | 2 | 2020 | 10 | 0.360 |
Why?
|
| Oculomotor Muscles | 2 | 2020 | 28 | 0.350 |
Why?
|
| Retrospective Studies | 10 | 2023 | 8489 | 0.330 |
Why?
|
| Middle Aged | 12 | 2019 | 25028 | 0.320 |
Why?
|
| Herpesvirus 1, Human | 3 | 2017 | 244 | 0.300 |
Why?
|
| Female | 12 | 2023 | 44532 | 0.290 |
Why?
|
| Male | 18 | 2023 | 40965 | 0.290 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 375 | 0.270 |
Why?
|
| Diagnosis, Differential | 4 | 2018 | 1565 | 0.260 |
Why?
|
| Blindness | 2 | 2018 | 41 | 0.260 |
Why?
|
| Antiviral Agents | 3 | 2018 | 510 | 0.250 |
Why?
|
| Vitreous Body | 1 | 2024 | 54 | 0.240 |
Why?
|
| Tomography, Optical Coherence | 3 | 2021 | 130 | 0.230 |
Why?
|
| Chronic Disease | 2 | 2018 | 971 | 0.230 |
Why?
|
| Slit Lamp Microscopy | 2 | 2019 | 5 | 0.230 |
Why?
|
| Macular Edema | 1 | 2023 | 50 | 0.230 |
Why?
|
| Play and Playthings | 1 | 2022 | 7 | 0.220 |
Why?
|
| Aged | 7 | 2020 | 18415 | 0.210 |
Why?
|
| Eye Injuries | 1 | 2022 | 15 | 0.210 |
Why?
|
| Tears | 1 | 2022 | 7 | 0.210 |
Why?
|
| Orbit | 2 | 2019 | 37 | 0.210 |
Why?
|
| Eye Banks | 1 | 2021 | 3 | 0.210 |
Why?
|
| Disease Management | 2 | 2021 | 327 | 0.200 |
Why?
|
| Proteomics | 1 | 2023 | 212 | 0.200 |
Why?
|
| Oxidative Stress | 2 | 2023 | 447 | 0.200 |
Why?
|
| Bandages | 2 | 2018 | 41 | 0.200 |
Why?
|
| Tissue Preservation | 1 | 2020 | 14 | 0.190 |
Why?
|
| Retinal Perforations | 1 | 2020 | 19 | 0.190 |
Why?
|
| Vitrectomy | 1 | 2020 | 52 | 0.190 |
Why?
|
| Glucocorticoids | 2 | 2023 | 352 | 0.190 |
Why?
|
| DNA, Protozoan | 1 | 2019 | 16 | 0.180 |
Why?
|
| Lymphoma | 1 | 2021 | 262 | 0.180 |
Why?
|
| Antiprotozoal Agents | 1 | 2019 | 33 | 0.180 |
Why?
|
| Consensus | 1 | 2021 | 335 | 0.180 |
Why?
|
| Hydrocodone | 1 | 2019 | 7 | 0.180 |
Why?
|
| Adult | 8 | 2023 | 25648 | 0.170 |
Why?
|
| Keloid | 1 | 2019 | 8 | 0.170 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2019 | 5 | 0.170 |
Why?
|
| Pilot Projects | 2 | 2019 | 839 | 0.170 |
Why?
|
| Orbital Implants | 1 | 2019 | 5 | 0.170 |
Why?
|
| Acetaminophen | 1 | 2019 | 54 | 0.170 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2019 | 11 | 0.170 |
Why?
|
| Optic Nerve | 2 | 2021 | 35 | 0.170 |
Why?
|
| Microscopy, Confocal | 1 | 2019 | 268 | 0.170 |
Why?
|
| Benzalkonium Compounds | 1 | 2018 | 2 | 0.170 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 185 | 0.170 |
Why?
|
| Polyps | 1 | 2019 | 28 | 0.170 |
Why?
|
| Loteprednol Etabonate | 1 | 2018 | 2 | 0.170 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2019 | 25 | 0.170 |
Why?
|
| Administration, Ophthalmic | 1 | 2018 | 9 | 0.170 |
Why?
|
| Antigens, CD20 | 1 | 2018 | 36 | 0.160 |
Why?
|
| Prednisolone | 1 | 2018 | 41 | 0.160 |
Why?
|
| Eye Diseases | 1 | 2018 | 53 | 0.160 |
Why?
|
| Orbital Fractures | 1 | 2018 | 13 | 0.160 |
Why?
|
| Diplopia | 1 | 2018 | 13 | 0.160 |
Why?
|
| Anti-Allergic Agents | 1 | 2018 | 39 | 0.160 |
Why?
|
| Optic Disk | 1 | 2018 | 13 | 0.160 |
Why?
|
| Anesthetics | 1 | 2018 | 48 | 0.160 |
Why?
|
| Incidence | 4 | 2019 | 1577 | 0.160 |
Why?
|
| Administration, Oral | 1 | 2019 | 684 | 0.160 |
Why?
|
| Corneal Topography | 1 | 2017 | 8 | 0.160 |
Why?
|
| Immunoenzyme Techniques | 1 | 2018 | 303 | 0.160 |
Why?
|
| Conjunctival Neoplasms | 1 | 2017 | 2 | 0.160 |
Why?
|
| Contact Lenses | 1 | 2017 | 7 | 0.160 |
Why?
|
| Antifungal Agents | 2 | 2016 | 117 | 0.160 |
Why?
|
| Photorefractive Keratectomy | 1 | 2017 | 4 | 0.160 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2017 | 10 | 0.150 |
Why?
|
| Eye Movements | 1 | 2018 | 119 | 0.150 |
Why?
|
| Keratitis, Dendritic | 1 | 2017 | 13 | 0.150 |
Why?
|
| Multiple Myeloma | 1 | 2021 | 307 | 0.150 |
Why?
|
| Surgeons | 1 | 2021 | 238 | 0.150 |
Why?
|
| Toxoplasmosis, Ocular | 1 | 2016 | 17 | 0.150 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 240 | 0.150 |
Why?
|
| Cnidarian Venoms | 1 | 2016 | 19 | 0.150 |
Why?
|
| Refractive Surgical Procedures | 1 | 2016 | 1 | 0.150 |
Why?
|
| Eye Infections | 1 | 2016 | 2 | 0.150 |
Why?
|
| Eye Burns | 1 | 2016 | 5 | 0.150 |
Why?
|
| Explosions | 1 | 2016 | 6 | 0.140 |
Why?
|
| Corneal Injuries | 1 | 2016 | 10 | 0.140 |
Why?
|
| Sclera | 1 | 2016 | 11 | 0.140 |
Why?
|
| Blast Injuries | 1 | 2016 | 11 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 1 | 2017 | 286 | 0.140 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 94 | 0.140 |
Why?
|
| Rhizopus | 1 | 2016 | 2 | 0.140 |
Why?
|
| Corneal Ulcer | 1 | 2016 | 6 | 0.140 |
Why?
|
| Cysticercosis | 1 | 2016 | 2 | 0.140 |
Why?
|
| Lacerations | 1 | 2016 | 28 | 0.140 |
Why?
|
| Eye Pain | 1 | 2015 | 4 | 0.140 |
Why?
|
| Dilatation, Pathologic | 1 | 2015 | 54 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 930 | 0.130 |
Why?
|
| Cocaine-Related Disorders | 1 | 2016 | 34 | 0.130 |
Why?
|
| Global Health | 2 | 2019 | 193 | 0.130 |
Why?
|
| Forecasting | 1 | 2016 | 304 | 0.130 |
Why?
|
| Intraocular Pressure | 1 | 2015 | 54 | 0.130 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2016 | 50 | 0.130 |
Why?
|
| Endoscopy | 1 | 2019 | 332 | 0.130 |
Why?
|
| Herpes Simplex | 1 | 2017 | 202 | 0.130 |
Why?
|
| Tuberculosis, Ocular | 1 | 2015 | 1 | 0.130 |
Why?
|
| Conjunctival Diseases | 1 | 2015 | 7 | 0.130 |
Why?
|
| Vision Disorders | 1 | 2015 | 75 | 0.130 |
Why?
|
| Pandemics | 1 | 2021 | 740 | 0.130 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2014 | 11 | 0.130 |
Why?
|
| Graft vs Host Disease | 1 | 2017 | 365 | 0.130 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2014 | 23 | 0.130 |
Why?
|
| Antibodies, Antinuclear | 1 | 2015 | 83 | 0.130 |
Why?
|
| Granuloma | 1 | 2015 | 65 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 413 | 0.130 |
Why?
|
| Retinal Diseases | 1 | 2016 | 90 | 0.130 |
Why?
|
| Biopsy | 1 | 2018 | 1163 | 0.120 |
Why?
|
| Staining and Labeling | 1 | 2014 | 165 | 0.120 |
Why?
|
| Nectins | 2 | 2010 | 9 | 0.120 |
Why?
|
| Papilledema | 1 | 2013 | 3 | 0.120 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2013 | 4 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 521 | 0.120 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2013 | 13 | 0.120 |
Why?
|
| Optic Chiasm | 1 | 2013 | 16 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 582 | 0.120 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 724 | 0.120 |
Why?
|
| Microbiota | 1 | 2018 | 381 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 2 | 2010 | 163 | 0.110 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2015 | 186 | 0.110 |
Why?
|
| Prevalence | 2 | 2016 | 1239 | 0.110 |
Why?
|
| Drug Resistance, Viral | 1 | 2012 | 51 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 2601 | 0.100 |
Why?
|
| Risk Factors | 1 | 2022 | 5417 | 0.100 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1195 | 0.100 |
Why?
|
| Population Surveillance | 1 | 2012 | 219 | 0.100 |
Why?
|
| Receptors, Virus | 1 | 2010 | 74 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2010 | 7 | 0.100 |
Why?
|
| Virus Attachment | 1 | 2010 | 6 | 0.090 |
Why?
|
| Sulfotransferases | 1 | 2010 | 19 | 0.090 |
Why?
|
| Heparitin Sulfate | 1 | 2010 | 27 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2016 | 751 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 1076 | 0.090 |
Why?
|
| Pseudopodia | 1 | 2010 | 35 | 0.090 |
Why?
|
| Animals | 5 | 2020 | 26582 | 0.090 |
Why?
|
| Receptors, Immunologic | 1 | 2010 | 135 | 0.090 |
Why?
|
| Endocytosis | 1 | 2010 | 177 | 0.090 |
Why?
|
| Glycoproteins | 1 | 2010 | 234 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 286 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 763 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 6509 | 0.080 |
Why?
|
| Acute Disease | 2 | 2021 | 826 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2016 | 1004 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2010 | 669 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3362 | 0.070 |
Why?
|
| Adolescent | 4 | 2018 | 8981 | 0.060 |
Why?
|
| Aqueous Humor | 1 | 2023 | 23 | 0.060 |
Why?
|
| Mass Spectrometry | 1 | 2023 | 188 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 894 | 0.050 |
Why?
|
| Leukemic Infiltration | 1 | 2021 | 14 | 0.050 |
Why?
|
| Refraction, Ocular | 1 | 2021 | 9 | 0.050 |
Why?
|
| Rupture, Spontaneous | 1 | 2021 | 43 | 0.050 |
Why?
|
| Descemet Stripping Endothelial Keratoplasty | 1 | 2021 | 19 | 0.050 |
Why?
|
| Ophthalmology | 1 | 2021 | 39 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 2232 | 0.050 |
Why?
|
| Health Policy | 1 | 2021 | 180 | 0.040 |
Why?
|
| Swine | 1 | 2020 | 555 | 0.040 |
Why?
|
| Child | 2 | 2023 | 6927 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 224 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2021 | 280 | 0.040 |
Why?
|
| Paranasal Sinuses | 1 | 2019 | 60 | 0.040 |
Why?
|
| Inflammation | 1 | 2023 | 920 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 288 | 0.040 |
Why?
|
| Cryotherapy | 1 | 2017 | 29 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 943 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2021 | 572 | 0.040 |
Why?
|
| Environment | 1 | 2018 | 219 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2023 | 2767 | 0.040 |
Why?
|
| Biomarkers | 1 | 2023 | 1718 | 0.040 |
Why?
|
| Facial Injuries | 1 | 2016 | 19 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2016 | 173 | 0.040 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 136 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 231 | 0.040 |
Why?
|
| Age Distribution | 1 | 2016 | 204 | 0.040 |
Why?
|
| Natamycin | 1 | 2016 | 1 | 0.040 |
Why?
|
| Fluconazole | 1 | 2016 | 10 | 0.040 |
Why?
|
| Microscopy, Acoustic | 1 | 2016 | 5 | 0.040 |
Why?
|
| Retinoschisis | 1 | 2016 | 3 | 0.040 |
Why?
|
| Cross-Linking Reagents | 1 | 2016 | 86 | 0.040 |
Why?
|
| Cysticercus | 1 | 2016 | 2 | 0.030 |
Why?
|
| Amphotericin B | 1 | 2016 | 34 | 0.030 |
Why?
|
| Asymptomatic Infections | 1 | 2016 | 16 | 0.030 |
Why?
|
| Tacrolimus | 1 | 2017 | 373 | 0.030 |
Why?
|
| Lens, Crystalline | 1 | 2016 | 69 | 0.030 |
Why?
|
| Tuberculin Test | 1 | 2015 | 5 | 0.030 |
Why?
|
| Cysts | 1 | 2016 | 104 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2017 | 996 | 0.030 |
Why?
|
| Antitubercular Agents | 1 | 2015 | 52 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1313 | 0.030 |
Why?
|
| Nasal Mucosa | 1 | 2015 | 186 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2016 | 225 | 0.030 |
Why?
|
| Vero Cells | 1 | 2013 | 100 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1686 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2016 | 695 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 320 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2013 | 89 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 977 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2013 | 782 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2010 | 21 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2016 | 2379 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 316 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 3046 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2705 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 3612 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2010 | 493 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 1961 | 0.020 |
Why?
|
| Virus Replication | 1 | 2010 | 319 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1753 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 504 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 2468 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 679 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 879 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2016 | 4213 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 2216 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 2360 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 2818 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 5976 | 0.020 |
Why?
|
| United States | 1 | 2016 | 6672 | 0.020 |
Why?
|